Literature DB >> 17457860

Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma.

Shin Hwang1, Sung-Gyu Lee, Deok-Bog Moon, Chul-Soo Ahn, Ki-Hun Kim, Young-Joo Lee, Tae-Yong Ha, Gi-Won Song.   

Abstract

Salvage liver transplantation has been performed for recurrent hepatocellular carcinoma (HCC) or deterioration of liver function after primary liver resection. Because prior liver resection per se is an unfavorable condition for living donor liver transplantation (LDLT), we assessed the technical feasibility of LDLT after prior hepatectomy, and we compared the outcome of salvage LDLT with that of primary LDLT in HCC patients. Of 342 patients with HCC, 17 (5%) underwent salvage LDLT, with 5 having undergone prior major liver resection and 12 prior minor resection. During salvage LDLT, 12 patients received right lobe grafts, 3 received left lobe grafts, and 2 received dual grafts. There was 1 incident (5.9%) of perioperative mortality. Recipient operation time was not prolonged in patients undergoing salvage LDLT, but bleeding complications occurred more frequently than in patients undergoing primary LDLT. Overall survival rates after salvage LDLT were similar to those after primary LDLT, especially when the extent of recurrent tumor was within the Milan criteria. These results indicate that every combination of prior hepatectomy and living donor liver graft is feasible for patients undergoing salvage LDLT, and the acceptable extent of HCC for salvage LDLT is equivalent to that for primary LDLT.

Entities:  

Mesh:

Year:  2007        PMID: 17457860     DOI: 10.1002/lt.21157

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  36 in total

1.  Living donor liver transplantation for hepatocellular carcinoma: defining criteria to extend indications.

Authors:  Irinel Popescu
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

Review 2.  Liver transplantation for hepatocellular carcinoma.

Authors:  See Ching Chan
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

3.  Make the right choice on primary treatments for salvage liver transplantation strategy.

Authors:  Hongyu Li; Bo Li
Journal:  Dig Dis Sci       Date:  2011-12       Impact factor: 3.199

4.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 5.  Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective.

Authors:  Young-In Yoon; Sung-Gyu Lee
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

6.  Prognostic impact of sarcomatous change of hepatocellular carcinoma in patients undergoing liver resection and liver transplantation.

Authors:  Shin Hwang; Sung-Gyu Lee; Young-Joo Lee; Chul-Soo Ahn; Ki-Hun Kim; Kwang-Min Park; Ki-Myung Moon; Deok-Bog Moon; Tae-Yong Ha; Eun-Sil Yu; Ga-Won Choi
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

Review 7.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 9.  Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation.

Authors:  See Ching Chan; Sheung Tat Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

Review 10.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.